Trial Profile

Preliminary randomized controlled trial of poractant alfa (Curosurf) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Poractant alfa (Primary)
Indications Adult respiratory distress syndrome; COVID 2019 infections; Pneumonia
Focus Therapeutic Use
Acronyms CAARDS-1

02 Feb 2021 Planned End Date changed from 30 Jan 2021 to 31 Jul 2021.
02 Feb 2021 Planned primary completion date changed from 30 Nov 2020 to 29 May 2021.
13 May 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com